PainReform (PRFX) announced the receipt of partial topline data from its contract research organization, CRO, Lotus Clinical Research, for the Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy. Initial analysis of the topline data indicates that PRF-110 demonstrated statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery. These findings underscore PRF-110’s potential to provide effective pain relief during the critical early postoperative period. However, data pertaining to the subsequent 24-hour period, which is essential for assessing the primary endpoint of the trial, is currently unclear due to incoherence of the data. PainReform is actively collaborating with Lotus to resolve this to complete the analysis of this portion of the data. At present, there can be no assurance that the effort to resolve the incoherence will be successful
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRFX:
- PainReform Announces 1-for-4 Reverse Share Split
- PainReform receives noncompliance notification from Nasdaq
- PainReform Faces Nasdaq Compliance Challenge Amid Drug Development
- PainReform cut to Hold at Maxim amid ‘changed’ market dynamics
- PainReform downgraded to Hold from Buy at Maxim
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
